Panorama del SARS-CoV-2 en 2023: ¿qué nos espera?
DOI:
https://doi.org/10.35839/repis.17.1.1728Palabras clave:
COVID-19; Therapeutics; Recommendations; New treatment; New findings.Descargas
Citas
CEPAL, OPS. Informe COVID-19: CEPAL-OPS [Internet]. COVID-19 Respuesta; 2021 [citado el 26 de enero de 2023]. Disponible en: https://repositorio.cepal.org/bitstream/handle/11362/47301/1/S2100594_es.pdf
PAHO-OMS. Virtual Press conference on global health issues transcript - 21 December 2022. [Internet]. USA; 2022 [citado el 26 de enero de 2023].Disponible en: https://www.who.int/publications/m/item/virtual-press-conference-on-global-health-issues-transcript---21-december-2022
CEPAL. Observatorio COVID-19 en América Latina y el Caribe el último siglo [Internet]. 2022. [citado el 26 de enero de 2023]. Disponible en: https://www.cepal.org/es/subtemas/covid-19
He X, Su J, Ma Y, Zhang W, Tang S. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Front Immunol [Internet]. 2022;13:1–24.doi:10.3389/fimmu.2022.945930
Le TTB, Vasanthakumaran T, Thi Hien HN, Hung I, Luu MN, Khan ZA, et al. SARS‐CoV‐2 Omicron and its current known unknowns: A narrative review. Rev Med Virol [Internet]. 2022;(August).doi:10.1002/rmv.2398
OMS. Seguimiento de las Variantes del SARS-CoV-2 [Internet]. USA; 2022 [citado el 26 de enero de 2023]. Disponible en:https://www.who.int/es/activities/tracking-SARS-CoV-2-variants
Arbel R, Sergienko R, Friger M, Peretz A, Beckenstein T, Yaron S, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med [Internet]. 2022;28(7):1486–90.doi:10.1038/s41591-022-01832-0
Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions Rashmi. Microbiol Res [Internet]. 2022;265. doi:10.1016/j.micres.2022.127204
Original C, Ba O, Covid- RNA, Original C, Ba O, Original C, et al. Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval [Internet]. 2022 [citado el 26 de enero de 2023].Disponible en: https://www.ema.europa.eu/en/news/adapted-vaccine-targeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval
Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet [Internet]. 2021;398(10318):2277–87. doi:10.1016/S0140-6736(21)02329-1
Tyndall JDA. S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2. J Med Chem [Internet]. 2022;65(9):217622. doi:10.1021/acs.jmedchem.2c00624
Davis HE, Mccorkell L, Vogel JM, Topol EJ. Long COVID : major findings , mechanisms and recommendations. Nat Rev Microbiol [Internet]. 2023. doi:10.1038/s41579-022-00846-2
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Juan S. SernaTrejos, Stefanya G. Bermúdez-Moyano , Diego G. Prado-Molina, Esteban Agudelo-Quintero

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.